Abbott wins FDA nod for Advisor HD Gridcardiac mapping cath

Abbott (NYSE:ABT) said today it won FDA clearance for is Advisor HD Grid mapping sensor enabled catheter designed for creating highly detailed maps of the heart. The newly cleared mapping catheter builds on the Abbott Park, Ill.-based company’s previous designs and and is intended to improve cardiac ablation procedures by providing an inside view of the heart for more accurate identification of the cardiac anatomy. The Advisor HD Grid catheter is designed to capture data including the direction and speed of cardiac signals, and allows for the creation of high-density maps of cardiac tissue for more optimal treatment regimens, Abbott said. The catheter’s sensor enabled technology can also improve accuracy of the cardiac image when paired with the company’s EnSite Precision cardiac mapping system, Abbott said. “At the University of Chicago Medicine, we are passionate about understanding and redefining arrhythmia mechanisms with higher resolution cardiac mapping. Abbott’s Advisor HD Grid represents an important step in the development of next generation mapping catheters. With a flexible and soft design using magnetic sensor technology, the catheter helps capture signals previous catheters may have missed to support the creation of highly detailed 3D maps of the heart. Innovation within the field of electrophysiology continues to evolve toward improving our ability to visualize arrhythmias in much greater detail, and we are confident that patien...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Catheters Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news